[시장보고서]급성 신손상 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

급성 신손상 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

Acute Kidney Injury Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

상품코드 : 1742538

리서치사 : Transparency Market Research

발행일 : 2025년 04월

페이지 정보 : 영문 199 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,366,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,698,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,029,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

급성 신손상 치료 시장 - 조사 범위

TMR의 조사 보고서 "세계 급성 신손상 치료 시장"은 2025년부터 2035년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회도 조사했습니다. 이 보고서는 2025년을 기준 연도, 2035년을 예측 연도로 하여 2019년부터 2035년까지의 세계 급성 신손상 치료 시장의 수익과 예측을 제공합니다. 또한, 2025-2035년까지의 세계 급성 신손상 치료 시장의 연평균 복합 성장률(CAGR %)을 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참고하여 급성 신손상 치료 시장을 이해하고자 했습니다.

시장 현황
2024년 시장 규모	36억 달러
2035년 시장 규모	82억 달러
CAGR	7.8%

이 보고서는 세계 급성 신손상 치료 시장의 경쟁 환경을 조사하고 있습니다. 세계 급성 신장 질환 치료 시장에서 활동하는 주요 업체를 식별하고, 각 업체는 다양한 속성별로 프로파일을 작성했습니다. 회사 개요, 재무 상태, 최근 동향, SWOT는 이 보고서에서 소개되는 세계 급성 신장 질환 치료 시장 기업의 속성입니다.

파이프라인 분석
주요 제품과 브랜드 분석
국가/지역별 규제 시나리오
주요 국가의 세계 질병 이환율과 발증률
AKI 유형별 사망률 - 세계와 주요 국가
최신 동향 - AKI 유형별
- 임상시험약(IND) - MTX652
- iNPC 유래 세포외소포(EV)를 이용한 AKI에 대한 EV 요법
- 급성 신손상(AKI) 조기 진단을 위한 바이오마커
- 지속적 신대체요법(CRRT)의 진보
- 신장 수복의 유전자 치료
- 실라스타틴에 의한 신장독소 유발성 급성 신손상 예방
- AKI 치료제 후보 - UNI-494
- RMC-035-IND(임상시험약)
- AKI의 인공지능
- 중간엽줄기세포 요법
경쟁사 제공 제품 벤치마크
Porter's Five Forces 분석
PESTEL 분석
신규 진출 기업(주로 OEM)의 제약·과제와 고려해야 할 주요 요인 및 비즈니스 모델에 관한 인사이트

제6장 세계의 시장 분석과 예측 : 약물요법별

소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 약물요법별, 2020-2035년
- 혈관 수축제
- 강심약
- 이뇨제
- 정맥내(IV) 정질액
- 면역억제제
- 기타
시장 매력 : 약물요법별

제7장 세계의 시장 분석과 예측 : 유형별

소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 유형별, 2020-2035년
- 신전성 급성 신손상
- 신내성 급성 신손상
- 신후성 급성 신손상
시장 매력 : 유형별

제8장 세계의 시장 분석과 예측 : 유통 채널별

소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 유통 채널별, 2020-2035년
- 병원 약국
- 소매 약국
- 온라인 약국
시장 매력 : 유통 채널별

제9장 세계의 시장 분석과 예측 : 지역별

주요 조사 결과
시장 금액 예측 : 지역별
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
시장 매력 : 지역별

제10장 북미의 시장 분석과 예측

미국
캐나다

제11장 유럽의 시장 분석과 예측

독일
영국
프랑스
스페인
이탈리아
기타 유럽

제12장 아시아태평양의 시장 분석과 예측

중국
일본
인도
호주와 뉴질랜드
기타 아시아태평양

제13장 라틴아메리카의 시장 분석과 예측

브라질
멕시코
기타 라틴아메리카

제14장 중동 및 아프리카의 시장 분석과 예측

GCC 국가
남아프리카공화국
기타 중동 및 아프리카

제15장 경쟁 구도

시장 기업 - 경쟁 매트릭스(기업 계층별·규모별)
시장 점유율 분석 기업별(2024)
기업 개요
- AM-Pharma
- Aptabio Therapeutics
- Arch Biopartners
- Novartis AG
- Guard Therapeutics
- Renibus Therapeutics
- Mission Therapeutics
- Unicycive Therapeutics Inc.
- Baxter International Inc.
- ICU Medical
- B. Braun Melsungen AG
- Fresenius Kabi
- Amanta Healthcare
- Pfizer, Inc.
- Sanofi S.A.

KSM

영문 목차

영문목차

Acute Kidney Injury Treatment Market - Scope of Report

TMR's report on the global acute kidney injury treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global acute kidney injury treatment market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute kidney injury treatment market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute kidney injury treatment market.

Market Snapshot
Market Value in 2024	US$ 3.6 Bn
Market Value in 2035	US$ 8.2 Bn
CAGR	7.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute kidney injury treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global acute kidney injury treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute kidney injury treatment market.

The report delves into the competitive landscape of the global acute kidney injury treatment market. Key players operating in the global acute kidney injury treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global acute kidney injury treatment market profiled in this report.

Key Questions Answered in global acute kidney injury treatment Market Report:

What is the sales/revenue generated by acute kidney injury treatment across all regions during the forecast period?
What are the opportunities in the global acute kidney injury treatment market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Acute Kidney Injury Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global acute kidney injury treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute kidney injury treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute kidney injury treatment market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Acute Kidney Injury Treatment Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, 2020-2035
- 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product & Brand Analysis
5.3. Regulatory Scenario by Country/Region
5.4. Disease Prevalence & Incidence Rate globally with key countries
5.5. Mortality Rate by Type of AKI- globally with key Countries
5.6. Emerging Trends - By Type of AKI
- 5.6.1. Investigational New Drug (IND) - MTX652
- 5.6.2. Extracellular Vesicle (EV) Therapy for AKI using iNPC-derived EV
- 5.6.3. Biomarkers for Early AKI Diagnosis
- 5.6.4. Continuous Renal Replacement Therapy (CRRT) Advancements
- 5.6.5. Gene Therapy in Kidney Repair
- 5.6.6. Prevention Of NephroToxin induced Acute Kidney injury with Cilastatin
- 5.6.7. Drug Candidate For the Treatment of AKI - UNI-494
- 5.6.8. RMC-035-IND (Investigational New Drug)
- 5.6.9. Artificial Intelligence in AKI
- 5.6.10. Mesenchymal Stem Cell Therapy
5.7. Benchmarking of the Products Offered by the Competitors
5.8. Porter's Five Forces Analysis
5.9. PESTEL Analysis
5.10. Insights on Restraints/Challenges & Major Factors for Considerations & Business Models for New Entrants (Mainly OEMs)

6. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Drug Therapy

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Therapy, 2020-2035
- 6.3.1. Vasoconstrictor Agents
- 6.3.2. Inotropic Drugs
- 6.3.3. Diuretics
- 6.3.4. Intravenous (IV) Crystalloid Solution
- 6.3.5. Immunosuppressive Drugs
- 6.3.6. Others
6.4. Market Attractiveness By Drug Therapy

7. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Type

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type, 2020-2035
- 7.3.1. Pre-renal Acute Kidney Injury
- 7.3.2. Intrinsic renal Acute Kidney Injury
- 7.3.3. Post-renal Acute Kidney Injury
7.4. Market Attractiveness By Type

8. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2020-2035
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
8.4. Market Attractiveness By Distribution Channel

9. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Region

9.1. Key Findings
9.2. Market Value Forecast By Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness By Region

10. North America Acute Kidney Injury Treatment Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast By Drug Therapy, 2020-2035
- 10.2.1. Vasoconstrictor Agents
- 10.2.2. Inotropic Drugs
- 10.2.3. Diuretics
- 10.2.4. Intravenous (IV) Crystalloid Solution
- 10.2.5. Immunosuppressive Drugs
- 10.2.6. Others
10.3. Market Value Forecast By Type, 2020-2035
- 10.3.1. Pre-renal Acute Kidney Injury
- 10.3.2. Intrinsic renal Acute Kidney Injury
- 10.3.3. Post-renal Acute Kidney Injury
10.4. Market Value Forecast By Distribution Channel, 2020-2035
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Online Pharmacies
10.5. Market Value Forecast By Country, 2020-2035
- 10.5.1. U.S.
- 10.5.2. Canada
10.6. Market Attractiveness Analysis
- 10.6.1. By Drug Therapy
- 10.6.2. By Type
- 10.6.3. By Distribution Channel
- 10.6.4. By Country

11. Europe Acute Kidney Injury Treatment Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast By Drug Therapy, 2020-2035
- 11.2.1. Vasoconstrictor Agents
- 11.2.2. Inotropic Drugs
- 11.2.3. Diuretics
- 11.2.4. Intravenous (IV) Crystalloid Solution
- 11.2.5. Immunosuppressive Drugs
- 11.2.6. Others
11.3. Market Value Forecast By Type, 2020-2035
- 11.3.1. Pre-renal Acute Kidney Injury
- 11.3.2. Intrinsic renal Acute Kidney Injury
- 11.3.3. Post-renal Acute Kidney Injury
11.4. Market Value Forecast By Distribution Channel, 2020-2035
- 11.4.1. Hospital Pharmacies
- 11.4.2. Retail Pharmacies
- 11.4.3. Online Pharmacies
11.5. Market Value Forecast By Country / Sub-region, 2020-2035
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Spain
- 11.5.5. Italy
- 11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
- 11.6.1. By Drug Therapy
- 11.6.2. By Type
- 11.6.3. By Distribution Channel
- 11.6.4. By Country / Sub-region

12. Asia Pacific Acute Kidney Injury Treatment Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast By Drug Therapy, 2020-2035
- 12.2.1. Vasoconstrictor Agents
- 12.2.2. Inotropic Drugs
- 12.2.3. Diuretics
- 12.2.4. Intravenous (IV) Crystalloid Solution
- 12.2.5. Immunosuppressive Drugs
- 12.2.6. Others
12.3. Market Value Forecast By Type, 2020-2035
- 12.3.1. Pre-renal Acute Kidney Injury
- 12.3.2. Intrinsic renal Acute Kidney Injury
- 12.3.3. Post-renal Acute Kidney Injury
12.4. Market Value Forecast By Distribution Channel, 2020-2035
- 12.4.1. Hospital Pharmacies
- 12.4.2. Retail Pharmacies
- 12.4.3. Online Pharmacies
12.5. Market Value Forecast By Country / Sub-region, 2020-2035
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
- 12.6.1. By Drug Therapy
- 12.6.2. By Type
- 12.6.3. By Distribution Channel
- 12.6.4. By Country / Sub-region

13. Latin America Acute Kidney Injury Treatment Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast By Drug Therapy, 2020-2035
- 13.2.1. Vasoconstrictor Agents
- 13.2.2. Inotropic Drugs
- 13.2.3. Diuretics
- 13.2.4. Intravenous (IV) Crystalloid Solution
- 13.2.5. Immunosuppressive Drugs
- 13.2.6. Others
13.3. Market Value Forecast By Type, 2020-2035
- 13.3.1. Pre-renal Acute Kidney Injury
- 13.3.2. Intrinsic renal Acute Kidney Injury
- 13.3.3. Post-renal Acute Kidney Injury
13.4. Market Value Forecast By Distribution Channel, 2020-2035
- 13.4.1. Hospital Pharmacies
- 13.4.2. Retail Pharmacies
- 13.4.3. Online Pharmacies
13.5. Market Value Forecast By Country / Sub-region, 2020-2035
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
- 13.6.1. By Drug Therapy
- 13.6.2. By Type
- 13.6.3. By Distribution Channel
- 13.6.4. By Country / Sub-region

14. Middle East & Africa Acute Kidney Injury Treatment Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast By Drug Therapy, 2020-2035
- 14.2.1. Vasoconstrictor Agents
- 14.2.2. Inotropic Drugs
- 14.2.3. Diuretics
- 14.2.4. Intravenous (IV) Crystalloid Solution
- 14.2.5. Immunosuppressive Drugs
- 14.2.6. Others
14.3. Market Value Forecast By Type, 2020-2035
- 14.3.1. Pre-renal Acute Kidney Injury
- 14.3.2. Intrinsic renal Acute Kidney Injury
- 14.3.3. Post-renal Acute Kidney Injury
14.4. Market Value Forecast By Distribution Channel, 2020-2035
- 14.4.1. Hospital Pharmacies
- 14.4.2. Retail Pharmacies
- 14.4.3. Online Pharmacies
14.5. Market Value Forecast By Country / Sub-region, 2020-2035
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
- 14.6.1. By Drug Therapy
- 14.6.2. By Type
- 14.6.3. By Distribution Channel
- 14.6.4. By Country / Sub-region

15. Competition Landscape

15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2024)
15.3. Company Profiles
- 15.3.1. AM-Pharma
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Financial Overview
  - 15.3.1.3. Financial Overview
  - 15.3.1.4. Business Strategies
  - 15.3.1.5. Recent Developments
- 15.3.2. Aptabio Therapeutics
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Financial Overview
  - 15.3.2.3. Financial Overview
  - 15.3.2.4. Business Strategies
  - 15.3.2.5. Recent Developments
- 15.3.3. Arch Biopartners
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Financial Overview
  - 15.3.3.3. Financial Overview
  - 15.3.3.4. Business Strategies
  - 15.3.3.5. Recent Developments
- 15.3.4. Novartis AG
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Financial Overview
  - 15.3.4.3. Financial Overview
  - 15.3.4.4. Business Strategies
  - 15.3.4.5. Recent Developments
- 15.3.5. Guard Therapeutics
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Financial Overview
  - 15.3.5.3. Financial Overview
  - 15.3.5.4. Business Strategies
  - 15.3.5.5. Recent Developments
- 15.3.6. Renibus Therapeutics
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Financial Overview
  - 15.3.6.3. Financial Overview
  - 15.3.6.4. Business Strategies
  - 15.3.6.5. Recent Developments
- 15.3.7. Mission Therapeutics
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Financial Overview
  - 15.3.7.3. Financial Overview
  - 15.3.7.4. Business Strategies
  - 15.3.7.5. Recent Developments
- 15.3.8. Unicycive Therapeutics Inc.
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Financial Overview
  - 15.3.8.3. Financial Overview
  - 15.3.8.4. Business Strategies
  - 15.3.8.5. Recent Developments
- 15.3.9. Baxter International Inc.
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Financial Overview
  - 15.3.9.3. Financial Overview
  - 15.3.9.4. Business Strategies
  - 15.3.9.5. Recent Developments
- 15.3.10. ICU Medical
  - 15.3.10.1. Company Overview
  - 15.3.10.2. Financial Overview
  - 15.3.10.3. Financial Overview
  - 15.3.10.4. Business Strategies
  - 15.3.10.5. Recent Developments
- 15.3.11. B. Braun Melsungen AG
  - 15.3.11.1. Company Overview
  - 15.3.11.2. Financial Overview
  - 15.3.11.3. Financial Overview
  - 15.3.11.4. Business Strategies
  - 15.3.11.5. Recent Developments
- 15.3.12. Fresenius Kabi
  - 15.3.12.1. Company Overview
  - 15.3.12.2. Financial Overview
  - 15.3.12.3. Financial Overview
  - 15.3.12.4. Business Strategies
  - 15.3.12.5. Recent Developments
- 15.3.13. Amanta Healthcare
  - 15.3.13.1. Company Overview
  - 15.3.13.2. Financial Overview
  - 15.3.13.3. Financial Overview
  - 15.3.13.4. Business Strategies
  - 15.3.13.5. Recent Developments
- 15.3.14. Pfizer, Inc.
  - 15.3.14.1. Company Overview
  - 15.3.14.2. Financial Overview
  - 15.3.14.3. Financial Overview
  - 15.3.14.4. Business Strategies
  - 15.3.14.5. Recent Developments
- 15.3.15. Sanofi S.A.
  - 15.3.15.1. Company Overview
  - 15.3.15.2. Financial Overview
  - 15.3.15.3. Financial Overview
  - 15.3.15.4. Business Strategies
  - 15.3.15.5. Recent Developments